Pharmacological Interventions for Acute Pancreatitis in Adults: An Overview of Systematic Reviews
Journal of Evidence-Based Medicine · 2025-03 · 18 (1)
DOI: 10.1111/jebm.70007 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Evidence-Based Medicine, online erschienen am 04.03.2025. Verfasst von Ling Ding und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chinese Evidence-Based Medicine Center and Cochrane China Center, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospit…. Hauptthemen laut MEDLINE: Pancreatitis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Aim
To provide a comprehensive assessment of the efficacy and safety of pharmacological interventions for AP.
Methods
This was an overview of systematic reviews based on randomized controlled trials comparing pharmacological interventions with placebo or blank control in adults with AP. We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews from inception to January 13, 2024, with an update on February 4, 2025. The effect value of each medication on each outcome of interest defined as a “combo” was assessed. Findings were categorized as efficacious, not efficacious, or inconclusive.
Results
Fifteen reviews (167 unique trials, 12,930 participants) reported the efficacy of 14 medications on 5 outcomes, yielding 35 distinct combos. Seven combos showed efficacy with low certainty evidence: low molecular weight heparin (risk ratio 0.31, 95% confidence interval, 0.18–0.51), omega‐3 fatty acids (0.30, 0.14–0.65), and antioxidants (0.69, 0.49–0.98) for mortality; low molecular weight heparin (0.38, 0.22–0.65), chengqi‐series decoctions (0.48, 0.36–0.63), and ulinastatin (0.43, 0.24–0.78) for multiple organ failure; and neostigmine (mean difference –2.81, 95 % confidence interval –3.75 to –1.87) for length of intensive care unit stay. Half of the remaining combos showed no efficacy, while the other half was inconclusive for very low certainty evidence. Safety data were limited, with one review reporting no significant adverse events for neostigmine.
Conclusions
Some pharmacological interventions exhibited potential efficacy for specific AP outcomes, albeit with low certainty evidence. Further verifying those medications is crucial in advancing the treatment landscape for AP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chinese Evidence-Based Medicine Center and Cochrane China Center, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.
- NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, China.
- Sichuan Center of Technology Innovation for Real World Data, Chengdu, China.
- West China School of Medicine, Sichuan University, Chengdu, China.
- West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Jiayue Xu, Yuning Wang, Xin Sun
Zitieren
APA
Ding, L., Jian, L., Xu, J., He, Q., Wang, Y., Sun, C., Wang, W., & Sun, X. (2025). Pharmacological Interventions for Acute Pancreatitis in Adults: An Overview of Systematic Reviews. Journal of Evidence-Based Medicine, 18(1). https://doi.org/10.1111/jebm.70007
Vancouver
Ding L, Jian L, Xu J, He Q, Wang Y, Sun C, et al. Pharmacological Interventions for Acute Pancreatitis in Adults: An Overview of Systematic Reviews. Journal of Evidence-Based Medicine. 2025;18(1). doi:10.1111/jebm.70007
BibTeX
@article{Ding2025,
author = {Ding, Ling and Jian, Linge and Xu, Jiayue and He, Qiao and Wang, Yuning and Sun, Che and Wang, Wen and Sun, Xin},
title = {Pharmacological Interventions for Acute Pancreatitis in Adults: An Overview of Systematic Reviews},
journal = {Journal of Evidence-Based Medicine},
year = {2025},
volume = {18},
number = {1},
doi = {10.1111/jebm.70007}
}
EUVIMED